Navigation Links
Experimental Drug Fights Multiple Sclerosis Activity
Date:6/20/2008

It led to a reduction of lesions seen on MRIs with limited side effects, study found

FRIDAY, June 20 (HealthDay News) -- One of the first pills to treat the "relapse-remitting" form of multiple sclerosis has been shown to help fight the disease with few side effects.

Although the drug, laquinimod, is still experimental, having a pill available would make therapy much more convenient for many patients.

"By and large, this doesn't look as strong as the strongest injectable drugs like Tysabri... but, in general, I believe that patients and companies feel that the advantage of having an oral drug makes these attractive additions to our therapeutic armamentarium," said Dr. John Richert, executive vice president for research and clinical programs at the National Multiple Sclerosis Society.

"Patients are more likely to stay on an oral drug. We'll need to see what comes out of Phase 3 trials [the current trial was a Phase 2 study]. At this point, it's encouraging, and certainly patients are thirsting for oral options," Richert added.

The study, funded by Teva Pharmaceutical Industries, is published in the June 21 issue of The Lancet. Earlier results from the same trial were presented this spring at the annual meeting of the American Academy of Neurology.

Multiple sclerosis affects the central nervous system and is thought to be an autoimmune disease. It primarily strikes "white matter" -- the tissues in the brain and the other parts of the nervous system that transmit messages between "gray matter," where nerve bodies are found. Symptoms range from the mild (numbness in the limb) to severe, including paralysis and loss of vision. There are four different "courses" of the disease, the most common being relapse-remitting MS, in which flare-ups alternate with partial or complete remissions.

Several treatments are available for MS; all are injectable.

Testing of an earlier, related oral drug called Linomide (roquinimex) was stopped during Phase 3 trials when the compound was linked to a high incidence of heart problems, including heart attacks. The trial lasted long enough, however, to show that the drug had benefit, Richert said.

"That information served as impetus for researchers to go back to the laboratory and try to engineer out the cardiac toxic part of the molecule but maintain the immunomodulatory effects that were beneficial for an autoimmune disease like multiple sclerosis," Richert explained. "That is how laquinimod was born."

Laquinimod works by binding to receptors on immune cells, isolating them in the lymph nodes, thereby reducing their ability to cause the damage associated with MS symptoms.

The nine-country study involved 306 patients aged 18 to 50 who were randomly assigned to receive either a placebo, 0.3 milligrams of laquinimod or 0.6 milligrams of laquinimod daily.

People with the higher dose of laquinimod had a 40.4 percent reduction in the number of lesions -- indicating disease activity -- seen on MRI scans. The lower dose had no significant benefit.

There were two side effects, both of them reversible. Two patients stopped taking the drug because they developed liver problems, the researchers said.

A Phase 3 trial is currently under way, said the study authors, from the Institute of Experimental Neurology at the University Vita-Salute in Milan, Italy.

"Certainly there have been Phase 2 drugs that have looked OK that have failed in Phase 3," Richert said. "There's always a significant amount of guesswork in trying to predict how things are going to end up."

More information

Visit the National Multiple Sclerosis Society for more on this disease.



SOURCES: John Richert, M.D., executive vice president for research and clinical programs, National Multiple Sclerosis Society, New York City; June 21, 2008, The Lancet


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
2. Experimental Antidepressants Offer Faster Relief
3. Experimental drug shows promise in advanced kidney cancer
4. Experimental drug boosts survival in recurrent ovarian cancer
5. Experimental cancer pharmaceuticals under trial
6. Experimental Drug Fails Against Heart Failure
7. Experimental Drug Fights Prostate Cancer
8. Experimental technique at GUMC offers real-time analysis of breast cancer biopsies
9. Experimental Vaccine Halts Prostate Cancer in Mice
10. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
11. 52 minority scientists receive travel fellowships to Experimental Biology 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Drug Fights Multiple Sclerosis Activity
(Date:2/20/2017)... ... ... Clearwave is the leading provider in patient ... of touch screen terminals. Both companies will be showcasing their solutions at Posiflex ... Posiflex is helping to bridge the gap between healthcare hardware and software through ...
(Date:2/20/2017)... Sunapee, NH (PRWEB) , ... February 20, 2017 , ... ReportingMD, a Population Health Software ... rapid growth of the company. The new location will triple the size of the ... location for the town of Sunapee, NH. , “We are excited to expand ...
(Date:2/20/2017)... FL (PRWEB) , ... February 20, 2017 , ... ... gift from Constellation Brands to purchase a new ultrasound-enhanced thrombolysis machine, a state-of-the-art ... waves. The gift was facilitated by the Pepin Family Foundation. , “We greatly ...
(Date:2/19/2017)... ... February 19, 2017 , ... Orbita, Inc., a ... with Healthwise ® at HIMSS 2017 to showcase a breakthrough ... health education, technology and services, will demonstrate a voice-powered knowedge assistant based on ...
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter President, Joette White, ... Pet Life Radio network. The episode, which was posted this week, features a ... factors led to Park Cities Pet Sitter’s being awarded the 2017 National Association of ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... PUNE, India , February 17, 2017 ... Product (Airborne Particle Counters, Liquid Particle Counters), Application (Cleanroom Monitoring, Contamination ... Global Forecast to 2021" published by MarketsandMarkets, the market is expected ... in 2016, at a CAGR of 3.7% from 2016 to 2021. ... ...
(Date:2/17/2017)... 2017 Research and Markets has announced the addition ... report to their offering. ... report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , and Rest of World. Annual estimates and forecasts ... analysis is provided for these markets. Market data and analytics are derived ...
(Date:2/17/2017)...   FormFast , the leader in electronic forms ... Engage , one of the largest MEDITECH partners ... will serve as the forms automation and electronic signature ... .  FormFast is a MEDITECH collaborative ... enhance the electronic health record. FormFast,s technology bridges clinical ...
Breaking Medicine Technology: